Endogenous testosterone and mortality in male hemodialysis patients: Is it the result of aging?

Clinical Journal of the American Society of Nephrology

Volumn 5, Issue 11, 2010, Pages 2018-2023

  Gungor, Ozkan ^a   Kircelli, Fatih ^a   Carrero, Juan Jesus ^b   Asci, Gulay ^a   Toz, Huseyin ^a   Tatar, Erhan ^a   Hur, Ender ^a   Sever, Mehmet Sukru ^c,d   Arinsoy, Turgay ^c,e   Ok, Ercan ^a,c  

^a EGE UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Fresenius Medical Care   (Turkey)

^d ISTANBUL UNIVERSITY   (Turkey)

^e GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; TESTOSTERONE;

ADULT; AGING; ANDROGEN DEFICIENCY; ARTICLE; BODY MASS; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; FOLLOW UP; GROUPS BY AGE; HEMODIALYSIS PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEN'S HEALTH; MORTALITY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PREDICTOR VARIABLE; SURVIVAL RATE; TESTOSTERONE BLOOD LEVEL; TURKEY (REPUBLIC);

ADULT; AGE FACTORS; AGED; AGING; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RENAL DIALYSIS; RISK ASSESSMENT; RISK FACTORS; TESTOSTERONE; TIME FACTORS; TREATMENT OUTCOME; TURKEY;

EID: 78149348155     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03600410     Document Type: Article

References (37)

1. Yeap BB: Testosterone and ill-health in aging men. Endocrinol Metab 5: 113-121, 2009
2. Yeap BB: Are declining testosterone levels a major risk factor for ill-health in aging men? Int J Impot Res 21: 24-36, 2009
3. Eckardstein A, Wu FC: Testosterone and atherosclerosis. Growth Horm IGF Res 13[Suppl A]: S72-S84, 2003
4. Shabsigh R, Katz M, Yan G, Makhsida N: Cardiovascular issues in hypogonadism and testosterone therapy. Am J Cardiol 96: 67M-72M, 2005
5. Jones TH, Saad F: The effect of testosterone on risk factors for and the mediators of the atherosclerotic process. Atherosclerosis 207: 318-327, 2009
6. Bain J: The many faces of testosterone. Clin Interv Aging 2: 567-576, 2007
7. Stanworth RD, Jones TH: Testosterone for the aging male: Current evidence and recommended practice. Clin Interv Aging 3: 25-44, 2008
8. Laughlin GA, Barrett-Connor E, Bergstrom J: Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 93: 68-75, 2008
9. Araujo AB, Kupelian V, Page ST, Handelsman DJ, Bremner WJ, McKinlay JB: Sex steroids and all-cause and cause-specific mortality in men. Arch Intern Med 25: 1252-1260, 2007
10. Haring R, Völzke H, Steveling A, Krebs A, Felix SB, Schöfl C, Dörr M, Nauck M, Wallaschofski H: Low serum testosterone levels are associated with increased of mortality in a population-based cohort of men aged 20-79. Eur Heart J 31: 1494-1501, 2010
11. Shores MM, Moceri VM, Gruenewald DA, Brodkin KI, Matsumoto AM, Kivlahan DR: Low testosterone is associated with decreased function and increased mortality risk: A preliminary study of men in a geriatric rehabilitation unit. J Am Geriatr Soc 52: 2077-2081, 2004
12. Khaw KT, Dowsett M, Folkerd E, Bingham S, Wareham N, Luben R, Welch A, Day N: Endogenous testosterone and mortality due to all-causes, cardiovascular disease and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 116: 2694-2701, 2007
13. Gruenewald DA, Matsumoto AM: Testosterone supplementation therapy for older men: potential benefits and risks. J Am Geriatr Soc 51: 101-115, 2003
14. Bellinghieri G, Santoro D, Mallamace A, Savica V: Sexual dysfunction in chronic renal failure. J Nephrol 13: S113-S117, 2008
15. Karakitsos D, Patrianakos AP, De Groot E, Boletis J, Karabinis A, Kyriazis J, Samonis G, Parthenakis FI, Vardas PE, Daphnis E: Androgen deficiency and endothelial dysfunction in men with end-stage kidney disease receiving maintenance hemodialysis. Am J Nephrol 26: 536-543, 2006
16. Carrero JJ, Qureshi AR, Parini P, Arver S, Lindholm B, Bárány P, Heimbürger O, Stenvinkel P: Low serum testosterone increase mortality risk among male dialysis patients. J Am Soc Nephrol 20: 613-620, 2009
17. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N, European Uremic Toxin Work Group: Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20: 1048-1056, 2005
18. Albaaj F, Sivalingham M, Haynes P, McKinnon G, Foley RN, Waldek S, O'Donoghue DJ, Kalra PA: Prevalence of hypogonadism in male patients with renal failure. Postgrad Med J 82: 693-696, 2006
19. Johansen KL: Testosterone metabolism and replacement therapy in patients with end-stage renal disease. Semin Dial 17: 202-208, 2004 (Pubitemid 38824501)
20. Tostain JL, Blanc F: Testosterone deficiency: A common, unrecognized syndrome. Nat Clin Pract Urol 5: 388-396, 2008
21. Araujo AB, Esche GR, Kupelian V, O' Donell AB, Travison TG, Williams RE, Clark RV, McKinlay JB: Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 92: 4241-4247, 2007
22. Kurnatowska I, Zygmunt A, Fijałkowska-Morawska J, Białkowska J, Jabłkowski M, Nowicki M, Lewiński A: Hormonal activity of the hypophysial-gonadal axis versus the mineral bone density and specific markers of bone turnover in hemodialysis population [in Polish]. Pol Merkur Lekarski 20: 408-412, 2006
23. Sobki SH, Al-Etah H, El Gezeery A, Al Khader A: Effect of age on pituitary gonadal hormonal responses of Saudi male patients on hemodialysis. Saudi J Kidney Dis Transpl 15: 447-454, 2004
24. Palmer BF: Sexual dysfunction in men and women with chronic kidney disease and end-stage kidney disease. Adv Ren Replace Ther 10: 48-60, 2003 (Pubitemid 36278330)
25. Feldman HA, Longcope C, Derby CA, Johannes CB, Araujo AB, Coviello AD, Bremner WJ, McKinlay JB: Age trends in the level of serum testosterone and other hormones in middle-aged men: Longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 87: 589-598, 2002
26. Schulze JJ, Rane A, Ekström L: Genetic variation in androgen disposition: Implications in clinical medicine including testosterone abuse. Expert Opin Drug Metab Toxicol 5: 731-744, 2009
27. Brambilla DJ, Matsumoto AM, Araujo AB, McKinlay JB: The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men. J Clin Endocrinol Metab 94: 907-913, 2009
28. Kupelian V, Page ST, Arauio AB, Travison TG, Bremner WJ, McKinlay JB: Low sex hormone-binding globulin, total testosterone, and symptomatic androgen deficiency are associated with development of the metabolic syndrome in nonobese men. J Clin Endocrinol Metab 91: 843-850, 2006
29. Schubert M, Jockenhövel F: Testosterone and metabolic syndrome. Urologe A 49: 47-50, 2010
30. Jensen TK, Andersson AM, Jorgensen N, Andersen AG, Carlsen E, Petersen JH, Skakkebaek NE: Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 82: 863-870, 2004
31. Isidori AM, Caprio M, Strollo F, Moretti C, Frajese G, Isidori A, Fabbri A: Leptin and androgens in male obesity: Evidence for leptin contribution to reduced androgen levels. J Clin Endocrinol Metab 84: 3673-3680, 1999
32. Kley HK, Edelmann P, Kruskemper HL: Relationship of plasma sex hormones to different parameters of obesity in male subjects. Metabolism 29: 1041-1045, 1980 (Pubitemid 11232199)
33. Miller KK: Androgen deficiency: Effects on body composition. Pituitary 12: 116-124, 2009
34. Carrero JJ, Cordeiro AC, Lindholm B, Stenvinkel P: The emerging pleiotrophic role of adipokines in the uremic phenotype. Curr Opin Nephrol Hypertens 19: 37-42, 2010
35. Johansen KL, Painter PL, Sakkas GK, Gordon P, Doyle J, Shubert T: Effects of resistance exercise training and nandrolone decanoate on body composition and muscle function among patients who receive hemodialysis: A randomized, controlled trial. J Am Soc Nephrol 17: 2307-2314, 2006
36. Johansen KL, Mulligan K, Schambelan M: Anabolic effects of nandrolone decanoate in patients receiving dialysis: A randomized controlled trial. JAMA 281: 1275-1281, 1999
37. Brockenbrough AT, Dittrich MO, Page ST, Smith T, Stivelman JC, Bremner WJ: Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease. Am J Kidney Dis 47: 251-262, 2006